Longitudinal analysis of ctDNA, at 4 subsequently time points, by ddPCR showed a progressive disappearance of this mutation following the treatment with BRAF + MEK inhibitors, in line with the patient showing stable disease, thus confirming the clinical utility of this targeted approach in sarcoma treatment [42, 43]. This evidence concerns the gene MAP2K7 and sarcoma.